{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:37:39Z","timestamp":1783312659069,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.oret.2017.11.012","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:53:46Z","timestamp":1514940826000},"page":"858-863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity"],"prefix":"10.1016","volume":"2","author":[{"given":"Odalis","family":"Ar\u00e1mbulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Iturralde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o B.","family":"Fortes Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2017.11.012_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(97)01107-0","article-title":"Retinopathy of prematurity in middle-income countries","volume":"350","author":"Gilbert","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2017.11.012_bib2","first-page":"26","article-title":"Childhood blindness","volume":"3","author":"Steinkuller","year":"1999","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.oret.2017.11.012_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.oret.2017.11.012_bib4","first-page":"1687","article-title":"Prevalence of retinopathy of prematurity in Latin America","volume":"5","author":"Carrion","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.oret.2017.11.012_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archopht.121.12.1769","article-title":"Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Fielder","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","article-title":"Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment","volume":"29","author":"Sanghi","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.oret.2017.11.012_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","article-title":"Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease","volume":"142","author":"Flynn","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"4 Suppl","key":"10.1016\/j.oret.2017.11.012_bib10","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity","volume":"30","author":"Drenser","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oret.2017.11.012_bib11","first-page":"373","article-title":"Zone I retinopathy of prematurity","volume":"4","author":"Katz","year":"2004","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.oret.2017.11.012_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone 1 retinopathy of prematurity","volume":"81","author":"O'Keefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.oret.2017.11.012_bib13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2017.11.012_bib14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.11.012_bib15","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A\u00a0systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2017.11.012_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3928\/01913913-20150216-01","article-title":"Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years","volume":"52","author":"Klufas","year":"2015","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.oret.2017.11.012_bib17","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.11.012_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2017.11.012_bib21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tjo.2012.10.001","article-title":"Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity. A preliminary report","volume":"2","author":"Lin","year":"2012","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib24","first-page":"2027","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity","volume":"29","author":"Ar\u00e1mbulo","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib26","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.11.012_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3928\/23258160-20161219-11","article-title":"Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity","volume":"48","author":"Day","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2017.11.012_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2017.11.012_bib29","doi-asserted-by":"crossref","first-page":"27082","DOI":"10.1038\/srep27082","article-title":"Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy","volume":"6","author":"Chan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2017.11.012_bib30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumb injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib32","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2017.11.012_bib33","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment \u2014 a review","volume":"100","author":"Hard","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.oret.2017.11.012_bib34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000101344","article-title":"Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity","volume":"91","author":"Th\u00e9baud","year":"2007","journal-title":"Neonatology"},{"key":"10.1016\/j.oret.2017.11.012_bib35","first-page":"457","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"Jang","year":"2010","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.oret.2017.11.012_bib36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreo-retinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"Lee","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2017.11.012_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653017304189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653017304189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:24:51Z","timestamp":1762853091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653017304189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2468653017304189"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2017.11.012","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}